Observational studyCancer medicine2025
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting.
Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Erdafitinib in Patients With Advanced Solid Tumors WithJCO precision oncology · 2026Trial
- Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSomatic FGFR gene alterations (FGFRalt) may act as oncogenic drivers across several cancers. The prognostic impact of FGFRalt in solid tumors is not fully understood. We assessed the prognostic impact of FGFRalt on overall survival (OS) in a tumor-agnostic real-world cohort of patients with advanced solid tumors.
methodsThis was a retrospective, observational, comparative cohort analysis that used data from a nationwide de-identified clinico-genomic database. Patients were included if they had advanced/metastatic disease, were aged ≥ 18 years at the time of diagnosis, had evidence of genomic testing for FGFRalt, and had initiated first-line systemic therapy for their cancer. Patients without FGFR alterations (FGFRneg) were matched 3:1 with patients with FGFRalt using a combination of exact matching on tumor type and Mahalanobis-distance matching on selected clinical confounders. The primary endpoint was OS from time of initiation of first-line therapy in patients with FGFRalt versus FGFRneg. To further mitigate bias, delayed entry models and covariate-adjusted stratified Cox models were implemented.
resultsThe final cohort included 1012 patients (253 FGFRalt, 759 FGFRneg), across 30 tumor types. There were no significant differences in real-world OS from first-line therapy between FGFRalt and FGFRneg groups (hazard ratio 0.97; p = 0.78). Median OS from initiation of first-line therapy was 1.13 years (95% confidence interval [CI] 0.92-1.52) and 1.01 years (0.89-1.15) for the FGFRalt and FGFRneg groups, respectively.
conclusionsIn this matched-cohort real-world analysis, presence of FGFRalt had no impact on the prognosis of patients with advanced solid tumors receiving standard-of-care treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.